MOTS-c Evidence Guide
Evidence for MOTS-c is too preliminary to support a research protocol with confidence. All published data comes from preclinical models and a single small human study that has not been independently replicated. The mitochondrial peptide concept is scientifically novel, but there is no established human dosing, pharmacokinetics, or safety profile. Of the Anti-Aging & Longevity compounds in this library, NAD+ precursors (NMN/NR) have substantially more human data as a starting point.
Our Take
Evidence for MOTS-c is too preliminary to support a research protocol with confidence. All published data comes from preclinical models and a single small human study that has not been independently replicated. The mitochondrial peptide concept is scientifically novel, but there is no established human dosing, pharmacokinetics, or safety profile. Of the Anti-Aging & Longevity compounds in this library, NAD+ precursors (NMN/NR) have substantially more human data as a starting point.
- Best for
- Mitochondrial biology research, insulin sensitization mechanistic studies (preclinical only)
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established human protocol - animal doses of 5mg/kg provide no reliable human translation
Benefits and Evidence
- Metabolic Homeostasis: Level D, mostly non-human evidence - Prevents diet-induced obesity and insulin resistance in mouse models through AMPK activation and enhanced glucose metabolism in skeletal muscle.
- Exercise Performance: Level D, mostly non-human evidence - Improved physical performance and endurance in aged mice, with effects comparable to regular exercise training. Circulating levels increase with exercise in humans.
- Cellular Stress Resistance: Level D, mostly non-human evidence - Enhances cellular stress resistance and promotes survival under metabolic stress conditions through nuclear translocation and ARE-mediated gene expression.
Side Effects and Warnings
- Limited safety data in humans
- No significant adverse effects reported in animal studies at therapeutic doses
- Extremely limited human data - preclinical research only
- No established human dosing or safety profile
- Quality and purity of commercially available peptide cannot be guaranteed
- Long-term effects of exogenous administration unknown
Research Dosage References
- <strong>Intraperitoneal injection (animal studies)</strong> - 5-15 mg/kg - Daily or 3 times weekly - Dosages from animal research only. No established human dosing. Human clinical trials have not been completed.
Mechanism of Action
MOTS-c acts as a mitochondrial-derived signaling peptide that translocates to the cell nucleus during metabolic stress, where it regulates nuclear gene expression through interaction with the antioxidant response element (ARE) and other stress-responsive promoter elements. This represents a novel form of mitochondria-to-nucleus retrograde signaling. The primary metabolic effects of MOTS-c are mediated through activation of AMP-activated protein kinase (AMPK), the master cellular energy sensor. AMPK activation by MOTS-c promotes glucose uptake in skeletal muscle, enhances fatty acid oxidation, and inhibits de novo lipogenesis - effects that mirror those of physical exercise. MOTS-c also inhibits the folate cycle and de novo purine biosynthesis, leading to accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), which is itself a potent AMPK activator. This creates a feedforward loop that amplifies the metabolic effects. Circulating levels of MOTS-c decline with age and are correlated with metabolic dysfunction, suggesting it may play a role in age-related metabolic decline. Exogenous administration in aged mice has been shown to improve physical performance and metabolic parameters.
Legal Status
Not FDA approved. Not scheduled. Available as a research peptide from specialty suppliers.